DAX25.421 +0,1%Est506.030 +0,2%MSCI World4.343 -0,1%Top 10 Crypto12,47 +0,4%Nas23.710 -0,1%Bitcoin81.575 -0,3%Euro1,1643 ±-0,0%Öl65,25 -0,3%Gold4.625 +0,8%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 TKMS thyssenkrupp Marine Systems TKMS00 NVIDIA 918422 Novo Nordisk A3EU6F Bayer BAY001 Deutsche Telekom 555750 DroneShield A2DMAA RENK RENK73 Siemens Energy ENER6Y BioNTech (ADRs) A2PSR2 Infineon 623100 Lufthansa 823212 SAP 716460 Allianz 840400 Amazon 906866
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nach US-Inflationsdaten: US-Börsen letztlich schwach -- DAX schließt kaum verändert -- EZB-Ausblick: Zinserhöhung unwahrscheinlich -- Palantir, AMD, Intel, Google, BioNTech, Rüstungsaktien im Fokus
Top News
Ausblick: Citigroup legt die Bilanz zum abgelaufenen Quartal vor Ausblick: Citigroup legt die Bilanz zum abgelaufenen Quartal vor
Analyst sieht Potenzial: Wells Fargo setzt 2026 auf diese Energie-Aktien Analyst sieht Potenzial: Wells Fargo setzt 2026 auf diese Energie-Aktien
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

CSL Aktie

Kaufen
Verkaufen
CSL Aktien-Sparplan
99,13 EUR +0,05 EUR +0,05 %
STU
92,31 CHF -1,01 CHF -1,08 %
BRX
CSL jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.48,76 Mrd. EUR

KGV25,01Div. Rendite1,89%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKN890952

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINAU000000CSL8

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolCMXHF

CSL Aktien News

DatumMeistgelesen
PR NewswireData Published in the New England Journal of Medicine Confirm the Long-term Durability and Safety of HEMGENIX® (etranacogene dezaparvovec-drlb) Over Five Years
PR NewswireCSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
PR NewswireCSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
Wer­bungCSL-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireCSL Honoured as Overall Winner of the 2025 Facility of the Year Awards by the International Society for Pharmaceutical Engineering (ISPE)
PR NewswireRecent RWE Data Show Cell-Based Influenza Vaccines Offer 20% Greater Protection in the Prevention of Test-Confirmed Influenza in Pediatric and Adult Populations Relative to Standard Egg-Based Infl...
PR NewswireCSL Behring Signs Letter of Intent with pan-Canadian Pharmaceutical Alliance (pCPA) for Public Reimbursement of HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy
Business TimesAustralian biotech giant CSL to spin off vaccine unit Seqirus, cut 15% of workforce
PR NewswireHealth Canada Has Authorized CSL's ANDEMBRY® (garadacimab) as Once-Monthly Treatment for Hereditary Angioedema (HAE)
PR NewswireU.S. Food and Drug Administration Approves CSL's ANDEMBRY® (garadacimab-gxii), the Only Prophylactic Hereditary Angioedema (HAE) Treatment Targeting Factor XIIa with Once-Monthly Dosing for All Pa...
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireEngland's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA Nephropathy
ZacksCarlyle Secured Lending Announces Completion of Merger With CSL III
PR NewswireCSL Receives Approval in Japan for ANDEMBRY® (garadacimab) Subcutaneous (S.C.) Injection 200mg Pens, a Novel Human Anti-Activated Factor XII Monoclonal Antibody for the Prevention of Acute Attacks...
PR NewswireEuropean Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine
PR NewswireEuropean Commission Approves CSL's ANDEMBRY® (garadacimab) for the Prevention of Recurrent Attacks of Hereditary Angioedema (HAE)
BenzingauniQure/ CSL Behring's Hemophilia Gene Therapy Shows Sustained Efficacy and Safety At Four Years
PR NewswireCSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B
PR NewswireCSL Receives Positive CHMP Opinion for Garadacimab in Hereditary Angioedema (HAE)
PR NewswireNew Data Presented at IDWeek 2024 Show Adjuvanted and High-Dose Influenza Vaccines are Comparable in Protecting Adults 65 Years of Age and Older Against Seasonal Influenza
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
PR NewswireCSL Seqirus Presents Data at IDWeek 2024 Highlighting the Urgent Need to Increase Influenza Vaccination Rates and the Benefits of Cell-Based Influenza Vaccines
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Sixth BARDA Award in Response to Avian Influenza
PR NewswireCSL Seqirus Presents Real-World Evidence at OPTIONS XII Conference Highlighting Effectiveness of Influenza Vaccinations
PR NewswireSelf-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination
PR NewswireCSL Seqirus, a Global Leader in Pandemic Preparedness, Announces Fifth BARDA Award in Response to Avian Influenza Outbreak
PR NewswireVeltassa® (patiromer) approved in Japan for the treatment of adults with hyperkalemia

CSL News

CSL News: auf dieser Seite finden Sie alle CSL News und Nachrichten zur CSL Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch CSL News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um CSL News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.